Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Oneoncology Research Network LLC

Neither a doctor nor a teaching hospital

Research payments

$4,160,766

200 payments

Through program year 2025, The Oneoncology Research Network LLC is reported as receiving $4,160,766 in research payments, across 200 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $4,049,942 193
2024 Research $110,824 7

Breakdown

Who paid Research payments · program years 2024–2025
  1. AstraZeneca Pharmaceuticals LP $3,287,651 40 payments
  2. Genmab A/S $231,961 69 payments
  3. AstraZeneca UK Limited $129,990 3 payments
  4. Genmab U.S., Inc. $123,350 14 payments
  5. Exelixis Inc. $117,414 34 payments
  6. F. Hoffmann-La Roche AG $104,300 13 payments
  7. Stemline Therapeutics Inc. $67,800 21 payments
  8. Hoffmann-La Roche Limited $56,550 2 payments
  9. Kite Pharma, Inc. $41,750 4 payments
Studies the money was for Research payments · program years 2024–2025
  1. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $1,518,051 4 payments
  2. A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 $345,440 2 payments
  3. Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. $285,781 2 payments
  4. A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) $239,144 3 payments
  5. A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) $231,961 69 payments
  6. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $175,982 3 payments
  7. A Master Protocol of an Open-Label Multi-Drug Multi-Centre Phase II Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma $162,902 3 payments
  8. Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer $137,352 3 payments
  9. a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 $129,990 3 payments
  10. Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors $117,414 34 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record